Full-Time

Regional Sales Director

Chronic Migraine/Spasticity & Movement Disorders, Neuroscience

Posted on 8/17/2026

AbbVie

AbbVie

10,001+ employees

Global biopharmaceutical company developing medicines

Compensation Overview

$178k - $321.5k/yr

+ Long-term incentive program

Florham Park, NJ, USA

Remote

Field-based role covering multiple states, with 50–75% overnight travel and residence within commutable distance of a major airport.

Bachelor's

Category
Sales & Account Management (1)
Required Skills
Marketing

Get referred to AbbVie

See people who can refer or advise you

Requirements
  • A bachelor's degree in health, sciences, pharmacy, or a business-related field is preferred, or relevant and equivalent industry experience is required.
  • Successful sales management experience and a positive track record of leading teams in the pharmaceutical industry are required.
  • Commercial pharmaceutical industry experience, such as physician or account-based selling, training, managed health care, and marketing, is required.
  • Ability to set a vision and strategy is required.
  • Ability to build and inspire individuals and teams for success is required.
  • Experience with project management is required.
  • Demonstrated ability to network and partner effectively across functional areas is required.
  • The candidate must satisfy applicable health care industry representative credentialing requirements and be in good standing or eligible to obtain the required credentials.
  • The candidate must have a valid driver's license, pass a pre-employment drug screening test, and meet safe-driving requirements.
Responsibilities
  • Achieve or exceed Neurosciences unit and dollar sales expectations and other organizational goals in alignment with United States marketing plans and expense, compliance, and legal guidelines.
  • Analyze sales and business execution to identify business needs, then develop and execute plans that provide tactical direction, evaluate progress, measure results, and monitor success to improve district, regional, and national sales performance.
  • Facilitate a culture built around performance and inclusion.
  • Develop, inspire, manage, retain, and promote team members while influencing and mentoring other individuals throughout the organization.
  • Collaborate with external customers and internal partners to use appropriate company resources to address customer needs and improve sales performance.
  • Meet national productivity and administrative requirements that support operational effectiveness and the sales and marketing strategy.
  • Provide direct feedback and manage or facilitate direct-report communications and feedback to brand partners and departments regarding marketing and other initiatives.
  • Assess and coach indication-specific anatomy, procedure, and injection training with working knowledge of the relevant information.
  • Drive a personal auto, company car or truck, or powered material-handling equipment.
Desired Qualifications
  • A minimum of 10 years of total business experience in healthcare, pharmaceutical, and/or biotechnology, including at least 5 years of management experience with high reimbursement components.
  • A documented history of driving strong team performance and coaching individuals for growth and development.
  • Experience selling or managing Buy & Bill, Specialty Pharmacy, Medicare Part B, and Medicare Part D products.
  • Experience selling or managing within headache and/or movement-disorder subspecialties.
  • A proven history of market and business planning, strategy development, and leading a team to execute the strategy successfully.
  • Ability to learn anatomical, procedural, and clinical information quickly and communicate, assess, and coach technical anatomical, procedural, and clinical information to varied audiences.
  • Ability to commit to 50–75% overnight travel and travel adequately for regional commitments, co-travels, conferences, training events, sales meetings, and other company events.
  • Ability and willingness to meet necessary hospital credentialing and vaccination requirements.

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • AbbVie filed SKYRIZI Crohn's subcutaneous induction with FDA on April 27, 2026.
  • AbbVie's June 22, 2026 Apogee acquisition adds asthma and dermatitis pipeline depth.
  • WCLC 2026 data showed 90% ABBV-1480 response rates, supporting Phase 3 advancement.

What critics are saying

  • Humira revenue plunged 47% in the U.S. during Q2 2026; biosimilars keep winning.
  • AbbVie still faces Humira antitrust and patent litigation, including Alvotech's active 2026 case.
  • ABBV-1480, Temab-A, and ABBV-706 remain unapproved; oncology failures would leave SKYRIZI-RINVOQ exposed.

What makes AbbVie unique

  • AbbVie's immunology franchise, SKYRIZI and RINVOQ, generated $8.79 billion in Q2 2026.
  • AbbVie converts 28.3% of revenue into free cash flow, funding buybacks and deals.
  • Botox, eye care, and neuroscience diversify earnings beyond immunology and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

3%

2 year growth

3%
Yahoo Finance
Aug 21st, 2026
AbbVie stock moves independently from market with 0.22 correlation driven by immunology drugs

AbbVie stock shows a correlation of just 0.22 to the S&P 500 over five years, meaning most of its movements stem from company-specific factors rather than broader market trends. The pharmaceutical firm's immunology segment generated nearly $8.8 billion of its $17 billion in second-quarter 2026 revenue, led by SKYRIZI at $5.5 billion and RINVOQ at over $2.5 billion. These treatments for chronic diseases have prices negotiated with payers, not consumers. AbbVie has delivered an annualised return of 21.5% with 23.5% volatility over five years, compared to the S&P 500's 12.9% return at 17.2% volatility. The company converts 28.3% of revenue into free cash flow, nearly double the S&P 500 median of 14.5%.

Grafa
Aug 21st, 2026
AbbVie reports 90% response in lung cancer study.

AbbVie reports 90% response in lung cancer study. * AbbVie reported a 90% objective response rate for ABBV-1480 plus platinum chemotherapy in squamous advanced NSCLC at the selected 10 mg/kg dose. * The same dose produced a 75.9% response rate in non-squamous disease and was selected as the recommended Phase 3 dose. * AbbVie will also present data for Temab-A and ABBV-706 across NSCLC and small cell lung cancer at the 2026 World Conference on Lung Cancer. AbbVie (NYSE:ABBV) reported Phase 1b lung cancer data showing objective response rates of 90% in squamous and 75.9% in non-squamous advanced NSCLC with ABBV-1480 plus platinum chemotherapy. At the 10 mg/kg dose, 27 of 30 patients with squamous disease and 22 of 29 with non-squamous disease achieved objective responses, according to the company. AbbVie said the findings support further evaluation of ABBV-1480 in advanced NSCLC and selected the 10 mg/kg regimen as the recommended Phase 3 dose. The company will present additional clinical results for telisotuzumab adizutecan, or Temab-A, in first-line non-squamous and EGFR-mutated NSCLC at the 2026 World Conference on Lung Cancer. AbbVie will also report ABBV-706 data in relapsed or refractory small cell lung cancer, including new safety analyses covering 240 patients. The company's conference presentations include real-world evidence evaluating SEZ6 as a potential therapeutic target in small cell lung cancer. The updates form part of AbbVie's clinical development program across non-small cell and small cell lung cancers, with several investigational therapies being evaluated across different treatment settings. Frequently asked questions. ABBV signals

Yahoo Finance
Aug 19th, 2026
AbbVie stock eyes breakout as Skyrizi dosing decision could unlock $24.5B revenue growth

AbbVie stock has returned 24.5% over the past three months, trading near its 52-week high. The pharmaceutical company's growth hinges on a pending regulatory decision for SKYRIZI, an immunology treatment that generates nearly a third of guided revenue. SKYRIZI sold $5.5 billion in Q2 2026, up 24% operationally. AbbVie guides the drug to $21.7 billion for 2026 against total company revenue of approximately $67.6 billion. The company has raised its 2026 guidance twice by $600 million combined. A subcutaneous induction option for Crohn's disease awaits regulatory approval this fall. Management expects the new dosing method to meaningfully accelerate SKYRIZI sales, though the commercial impact won't materialise until early 2027 due to contract timelines. Clinical trial results showed endoscopic response and remission rates 25 points above placebo.

BBC
Aug 19th, 2026
UK's Smith+Nephew CFO John Rogers to step down for external role.

UK's Smith+Nephew CFO John Rogers to step down for external role. August 19, 2026 The departure follows Smith+Nephew's decision weeks ago to cut its annual revenue growth forecast after second-quarter sales missed expectations due to weak U.S. knee and hip implant demand and pressure on skin substitute pricing International News via Reuters: Smith+Nephew said on Wednesday its finance chief John Rogers would step down at the end of September to take up an external position in the United States, ending his roughly two-and-a-half-year tenure with the medical products company. Here are some more details: - The departure follows Smith+Nephew's decision weeks ago to cut its annual revenue growth forecast after second-quarter sales missed expectations due to weak U.S. knee and hip implant demand and pressure on skin substitute pricing. - Smith+Nephew said it had appointed Senior Vice President Finance and Group Controller Pierre Palassian as interim chief financial officer until a permanent replacement was appointed. - Palassian, who joined Smith+Nephew in 2017, previously held senior roles at AbbVie and Abbott Laboratories. - Rogers, who took up the CFO role in early 2024, had relocated to the United States in 2025 for operational efficiencies. - Shares in the FTSE 100 company have gained nearly 14% during Rogers' tenure as CFO. - Smith+Nephew said Rogers would receive no severance payment, and that his outstanding incentive and share awards would lapse on September 30 under leaver rules. Reporting by Neeshita Beura in Bengaluru; Editing by Subhranshu Sahu - Advertisement - August 19, 2026 - Advertisement -

Right Brain Bio, Inc.
Aug 19th, 2026
Tavapadon update.

Tavapadon update. Publication of a Phase 3 trial of the dopamine agonist tavapadon in mild PD shows that a new option will be available soon for people with PD. Tavapadon is a unique dopamine agonist, stimulating different dopamine receptors than the currently available agents. What I think of as first generation dopamine agonists - the ones that are available now (ropinirole, pramipexole and rotigotine) act via D2/D3 receptors to reduce the brake on movement. In contrast, what I call second generation drug acts via D1/D5 receptors to stimulate movement. The trials that I expect to yield FDA approval for tavapadon studied the effects of the drug compared to placebo. They showed benefit in people with mild PD [TEMPO-2] as well as those with more advanced disease as defined by motor complications [TEMPO-3]. It is a strong database. But ParkinsonsDisease don't have data to tell ParkinsonsDisease how to use 1st -gen vs. this 2nd gen dopamine agonist. Open questions include: · Does one more potent improve movement than the other? · Is one approach better tolerated with less side effects? · Are there situations where a person should switch from 1st -gen to this 2nd -gen therapy? · Could the two together or rotating between the two be the optimal approach? With such unanswered questions, how are ParkinsonsDisease to know how to use this new therapy? Conducting proper randomized clinical trials focused on each question is the only way. Trials comparing similar drugs: feasible and important. Abbvie is developing tavapadon after it was initially discovered by scientists at Pfizer. As a commercial entity, why would Abbvie conduct comparative studies that risk their drug being shown to be no better than a 1st-gen dopamine agonist, especially considering how cheap they are compared to a newly launched brand-name drug? Consider a couple of lessons. 1. Several companies selling the cholesterol-lowering statins were battling for market share (behind Lipitor). Bristol-Myers Squibb (BMS) sought to increase its share and launched a large-scale, multi-center, blinded, randomized clinical trial comparing its drug (Pravachol) to Lipitor. No one expected the two drugs to have equal cholesterol lowering effects, as Lipitor more potently lowered cholesterol. Instead, the trial focused on whether the clinical impact of any cholesterol lowering were similar or different. When I spoke with cardiologists about the trial, they seemed convinced that BMS knew something that made them confident enough to spend the millions of dollars the trial would cost - and so continued to write prescriptions for Pravachol. In the end, Pravachol was shown to be inferior (though still better than placebo). BMS did the right thing, though their gamble failed. 2. When the second beta-blocker was approved for treatment of heart failure, GlaxoSmithKline (GSK) was concerned that its drug (Coreg) could lose market share - including to a generic beta-blocker. It launched a major clinical trial comparing its brand name drug to the generic. Again, doctors talking about the trial seemed convinced that GSK knew something that made it risk its beta-blocker franchise. In the end, Coreg was proven to be clinical superior to the generic beta-blocker metoprolol (that was also effective). GSK's did the right thing and their gamble paid off. Abbvie could to the right thing, but If such a trial is not already being planned, I am not optimistic Abbvie is likely to conduct such a trial. A call to action. If Abbvie has not already factored in this gamble to their soon to be launched drug, I am not optimistic they are likely to announce such a trial. But there is a way. The NIH, the Michael J. Fox Foundation, the Parkinson's Foundation and Cure Parkinson's - amongst others - could band together and make it happen. This is not merely a scientific curiosity. This is a major clinical need. And if you agree, tell these Foundations that you want to know the answers to these questions. In case you missed it... About Jonathan Sackner-Bernstein, MD Dr. Sackner-Bernstein shares his pursuit of conquering Parkinson's, using expertise developed as Columbia University faculty, FDA senior official, DARPA insider and witness to the toll of PD. Dr. S-B's Linkedin page RightBrainBio, Inc. was incorporated in 2022 to develop tranformative therapies for people with Parkinson's. I post on LinkedIn to highlight this weekly newsletter and engage in conversations with others. There was an old video of Michael J. Fox being interviewed by Barbara Walters about his ability and inability to control his movement.